High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
about
Optimized tumor cryptic peptides: the basis for universal neo-antigen-like tumor vaccinesNovel technologies and emerging biomarkers for personalized cancer immunotherapySingle-cell analysis tools for drug discovery and developmentNanotechnologies for biomedical science and translational medicineIntegrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of ImmunotherapyRecent advances in T-cell engineering for use in immunotherapyTumor neoantigens: building a framework for personalized cancer immunotherapyNeoantigens in cancer immunotherapy.Targeting of cancer neoantigens with donor-derived T cell receptor repertoires.Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer.Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes.Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set.Targeting the undruggable: immunotherapy meets personalized oncology in the genomic era.Targeting human melanoma neoantigens by T cell receptor gene therapyIdentification of immunotherapeutic targets by genomic profiling of rectal NET metastases.HPV disease transmission protection and control.Genetics and immunotherapy: using the genetic landscape of gliomas to inform management strategies.The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer.Unmasking targets of antitumor immunity via high-throughput antigen profiling.Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines.Current tools for predicting cancer-specific T cell immunity.Targeting neoantigens to augment antitumour immunity.Microbial HSP70 peptide epitope 407-426 as adjuvant in tumor-derived autophagosome vaccine therapy of mouse lung cancer.Targeting C-type lectin receptors: a high-carbohydrate diet for dendritic cells to improve cancer vaccinesIn silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cellsGuidelines for the use of flow cytometry and cell sorting in immunological studies.4-1BB-Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells.An Analysis of Natural T Cell Responses to Predicted Tumor Neoepitopes.Hitting the Target: How T Cells Detect and Eliminate Tumors.Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.Personalized cancer vaccines: Targeting the cancer mutanome.Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications.Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design
P2860
Q26738680-C10A4D07-6CFE-45DE-B77B-7A38CC882F21Q26770780-EA2ED03F-B2D7-4DB3-822D-876F29C346F4Q26775754-10C11663-40C3-40CC-B3DD-D30CDED3AD40Q26776376-25923A46-80EB-4C19-8224-2412A6154FBAQ26783783-C91BE3AF-995F-47C4-AE6C-14D6F8AB06F0Q28080312-FFBB005C-5370-4357-AB19-C2ABFABA3AE1Q28082704-6F3D7EDF-F4DD-4549-BB8B-5DF8F46204A8Q34470074-9BADD282-F179-40FA-B791-EC74C9BBA04EQ34677333-E88D9629-6558-4C0A-8B2C-89F2126890B6Q35980893-BED1BE01-B797-49E6-A6C9-AAAC6ABA0530Q36021163-58A6007A-06A9-43C8-A73C-08819DD925FDQ36050577-DF53FE09-F579-4555-B16F-1FD5FDEE5355Q36165605-B63D78E2-A61A-43BA-8D5C-E1390093B48BQ36173439-EB523190-2DA3-4F95-86D2-79695F833596Q36316627-A3DFB28A-655E-4CCE-A669-8A2BC7D430D5Q36618620-3F126EAF-5165-46A2-83B0-203EDD6BD087Q37477282-EEDC0ECA-1902-4792-9A96-A3EE31977C24Q37705703-3F2B5839-15B2-4139-868A-0F30D0DF40F2Q38362051-3B561BF0-E5E5-4993-9DAB-3D220E6BC302Q38753386-BF5C07DD-30B8-4B49-96E5-A18F48934146Q38787035-F4E8C4E7-1DDE-4F66-B0E7-9D762653FEFCQ38810264-3B275C88-1F66-4E5A-9E5E-F4C8062CC955Q38948897-EDE668A6-DDE2-4C67-A3E8-274CFA3C3833Q38953021-169A5AF8-6101-41EB-B5D0-9A5886E4A680Q39149196-1020CF82-2FA0-47A2-965B-ECA1832D50A6Q39357065-0C0122B0-CFB4-435D-90FD-C7EAA604C6ECQ39448911-7687E0DD-8D09-4432-9D63-8D8DADC5DBB0Q40188864-FA3CFE08-3612-49E1-A6AF-F4E9B374CF46Q41701367-FF34A54A-1120-4C4E-A510-37F52D87A765Q41918189-DD5FAA89-72AE-44D4-AD26-FDCAD773CCA1Q46863819-69E91710-918E-42F6-8E88-AE7BA7428ACFQ47162995-F14EDF2D-8950-4C37-8BAF-105EF22B14A9Q47222791-81C8EF06-82D1-455D-AE0D-4D347FA94ECEQ47947510-32A3648C-B7BC-4D97-8875-F856A4D39C38Q49956120-C3884A03-680B-4E29-B8D0-2A4B59BEF5BEQ50130464-AE8F8F40-39A9-45C3-89D4-3205C7F15442Q50222492-B3A46198-B944-4345-8EB4-EDF3C6860959Q58801376-F2B84FDB-EB34-49B0-8A1B-759156C15609
P2860
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
@ast
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
@en
type
label
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
@ast
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
@en
prefLabel
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
@ast
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
@en
P2860
P356
P1433
P1476
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
@en
P2093
Jorg Ja Calis
Marit M van Buuren
P2860
P304
P356
10.4161/ONCI.28836
P577
2014-05-14T00:00:00Z